XML 54 R33.htm IDEA: XBRL DOCUMENT
v3.8.0.1

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Oct. 19, 2017 | Oct. 31, 2015 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Significant Accounting Policies [Line Items] |  |  |  |  |
Common Stock, Par or Stated Value Per Share |  |  | $ 0.001 | $ 0.001 |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount |  |  | 76,848,199 | 23,532,492 | 19,778,424
Tax Rate Assumption Related To Deferred Tax Difference Reversal |  |  | The Company used tax rates of 39%, 24% and 23%. |  |
Maximum [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones | $ 320.0 |  |  |  |
Brazil [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Percentage Of Adult Gaucher Patients Treated With alfataliglicerase |  |  | 10.00% |  |
Pfizer Agreement [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Proceeds From Exchange For Rights To Royalties |  | $ 36.0 |  |  |
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage |  | 100.00% |  |  |
Chiesi Agreement [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Future research and development reimbursement |  |  | $ 25.0 |  |
Upfront Nonrefundable Noncreditable Payment Receivable | 25.0 |  |  |  |
Additional Amounts Payable To Cover Development Costs | 25.0 |  |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year | $ 10.0 |  |  |  |
Chiesi Agreement [Member] | Minimum [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Payment On Net Sales Percentage | 15.00% |  |  |  |
Chiesi Agreement [Member] | Maximum [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Payment On Net Sales Percentage | 35.00% |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The definition should be: "The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of research and development reimbursement payment + References No definition available. + Details
Name: | plx_FutureResearchAndDevelopmentReimbursement
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The maximum amount payable to entity to cover development costs in any year under agreement. + References No definition available. + Details
Name: | plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of adult Gaucher patients treated with Uplyso. + References No definition available. + Details
Name: | plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount received in exchange for rights to royalties. + References No definition available. + Details
Name: | plx_ProceedsFromExchangeForRightsToRoyalties
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. + References No definition available. + Details
Name: | plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |